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Abstract
Doxorubicin, daunorubicin and other anthracycline antibiotics constitute one of the most important groups of drugs used
today in cancer chemotherapy. The details of the drug interactions with membranes are of particular importance in the
understanding of their kinetics of passive diffusion through the membrane which is itself basic in the context of multidrug
 .resistance MDR of cancer cells. Anthracyclines are amphiphilic molecules possessing dihydroxyanthraquinone ring system
which is neutral under the physiological conditions. Their lipophilicity depends on the substituents. The amino sugar moiety
bears the positive electrostatic charge localised at the protonated amino nitrogen. The four anthracyclines used in this study
 .doxorubicin, daunorubicin, idarubicin and idarubicinol an idarubicin metabolite readily formed inside the cells have the
same amino sugar moiety, daunosamine, with pK of 8.4. Thus, all drugs studied will exhibit very similar electrostatica
interactions with membranes, while the major differences in overall drug-membrane behaviour will result from their
 .hydrophobic features. Circular dichroism CD spectroscopy was used to understand more precisely the conformational
 .aspects of the drug–membrane systems. Large unilamellar vesicles LUV consisting of phosphatidylcholine, phosphatidic
 .acid PA and cholesterol, were used. The anthracycline–LUV interactions depend on the molar ratio of phospholipids per
drug. At low molar ratios drug:PA, these interactions depend also on the anthracycline lipophilicity. Thus, both doxorubicin
and daunorubicin bind to membranes as monomers and their CD signal in the visible is positive. However, doxorubicin with
its very low lipophilicity binds to the LUV through electrostatic interactions, with the dihydroxyanthraquinone moiety being
in the aqueous phase, while daunorubicin, which is more lipophilic is unable to bind only through electrostatic interactions
and actually the hydrophobic interactions are the only detected. The highly hydrophobic idarubicin, forms within the bilayer
a rather complex entity involving 2–3 molecules of idarubicin associated in the right-handed conformation, one cholesterol
 .molecule and also molecule s of phosphatidic acid, as this special oligomeric species is not detected in the absence of
 .  .negatively-charged phospholipids. Idarubicinol differs from idarubicin with CH 13 –OH instead of C 13 5O and its
interactions with LUV are distinctly different. Its CD signal in the visible becomes negative and no self associations of the
 .molecule within the bilayer could be detected. The variation of the sign of the Cotton effect positive to negative may
 .  .  .  X.  .derive from the changes in the C 6a –C 7 –O 7 –C 1 dihedral angle. It is noteworthy that C 13 –OH group, which
strongly favours formation of the dimeric species in aqueous solutions when compared to idarubicin prevent association
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inside the LUV bilayer. At high ratios of phospholipids per drug all of them are embedded within the bilayer as monomer.
q 1998 Elsevier Science B.V.
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1. Introduction
Doxorubicin, daunorubicin and other anthracycline
antibiotics constitute one of the most important group
w xof drugs used today in cancer chemotherapy 1 .
Despite 20 years of widespread clinical usage, the
biological activities of the anthracyclines remain to
be fully elucidated and, to this end, characterisation
of their membrane interactions is of importance. In
this context, the interactions of anthracycline anti
cancer drugs like doxorubicin or daunorubicin with
membranes have been intensively studied with use of
various techniques including spectroscopic methods
w x2–18 . The anthracycline chromophore with its rich
set of the p“p )and n“p ) transitions sensitive
to the ring interactions with various molecules is very
attractive object especially for absorption, CD and
fluorescence spectroscopies.
The details of the drug interactions with mem-
branes are of particular importance in understanding
the kinetics of the passive diffusion of drug through
the membrane which is itself basic in the context of
 .multidrug resistance MDR of the cancer cells
w x14,19–21 . Previous studies have shown that the
degree of resistance, expressed by the resistant factor
of MDR cells towards antitumour drugs, decreases
when the kinetics of uptake increases and thus, in the
most of cases, when the lipophilicity of the molecule
w xincreases 20–23 . The role of anionic phospholipids
in the interaction of moderately lipophilic doxoru-
w xbicin with membrane has been widely studied 2–10 ,
while the interactions of highly lipophilic anthra-
cyclines such as idarubicin with biological mem-
branes are much less explored.
Anthracyclines are amphiphilic molecules possess-
ing dihydroxyanthraquinone ring system which is
neutral under the physiological conditions. Due to the
presence of different substituents, the lipophilicity of
the molecules can vary within a large scale. The
 .amino sugar moiety bound at C 7 site bears the
positive electrostatic charge localised at protonated
amino nitrogen. Four anthracycline drugs used in this
study including idarubicinol, an idarubicin metabolite
readily formed inside the cells and having antitumour
w xactivity comparable to that of idarubicin 24 , have
the same amino sugar moiety, daunosamine, with
pK of 8.4. This latter value is critical for thea
concentration of the neutral form of the drug, which
is able to enter inside the cell through the passive
diffusion mechanism. Thus, all drugs studied will
exhibit very similar electrostatic interactions with
membranes, while the major differences in overall
drug–membrane behaviour will result from their hy-
drophobic features.
Recently, using the observation that the anthra-
cycline fluorescence increases when drug becomes
embedded within the bilayer, we have determined the
partition coefficients and the binding constants of
several anthracycline derivatives to large unilamellar
w xvesicles 11 . The results have shown that, at high
phospholipid to drug molar ratio, anthracyclines were
embedded within the polar head of the bilayer and
that the efficiency of their incorporation in the bilay-
ers depended neither on the negative charge on the
membrane nor on the positive charge on the drug.
Both, the positively charged drugs as well as the
neutral ones have the same ability to be embedded
within the membrane bilayer. However, the percent-
age of each form present should depend on the
electrostatic parameters. In that respect fluorescence,
or more precisely microspectrofluorescence, was a
powerful technique to follow the drug behaviour in
the membrane. It did not, however, provide any
specific information about the drug structural confor-
mational changes during its interactions with the
bilayers.
To understand more precisely the conformational
aspects of the drug–membrane interactions, we have
applied circular dichroism spectroscopy and the re-
sults obtained are discussed in this paper. To compare
these results with those obtained earlier with use of
fluorescence techniques, the same composition of
large unilamellar vesicles consisting of phosphatidyl-
choline, phosphatidic acid and cholesterol, was used.
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2. Materials and methods
2.1. Drugs and chemicals
 .  .Doxorubicin DOX , idarubicin IDA , idarubici-
 .nol IDOL were kindly provided by Pharmacia and
 .Upjohn laboratory and daunorubicin DNR by Roger
Bellon laboratory. Stock solutions were prepared in
water just before the experiment. Concentrations were
determined by diluting stock solutions, in water to
approximately 10y 5 M and using « s480
y1 y1  .11,500 M cm . Egg phosphatidylcholine PC , egg
 .  .phosphatidic acid PA and cholesterol CHOL were
from Sigma. The experiments were performed at
20"28C in 0.05 M Hepes buffer at pH 7.2 in the
presence of 0.1 M KCl. All other reagents were of the
highest quality available, and deionized double-dis-
tilled water was used throughout the experiments.
2.2. Absorption and CD spectroscopy
 .Circular dichroism CD measurements were per-
formed using a Jobin Yvon Mark V dichrograph
equipped with a thermostated cell holder. Samples
were placed in quartz cuvette, 0.2 cm pathlength, and
incubated at 208C for 10 min prior to data acquisition.
Typically 3 scans were collected and 2–4 replicates
were made. Absorption spectra were recorded on a
Cary 219 spectrophotometer.
2.3. Preparation of liposomes
 .Large unilamellar vesicles LUV were prepared
on the day of an experiment by the method of
w xBarchfeld and Deamer 25 . Egg phosphatidylcholine,
phosphatidic acid, and cholesterol were combined at
PCrPArCHOL molar ratios of 95:5:0, 75:5:20,
55:5:40, 80:20:0, 75:20:5, 70:20:10, 65:20:15,
60:20:20, 55:20:25, 50:20:30, 45:20:35, and 40:20:40.
Organic solvents were removed by evaporation under
nitrogen gas and then vacuum. A film containing
45mmol of phospholipid was obtained. The lipid was
redissolved with 20 ml diethyl ether and 5 ml buffer
was added. The suspension was sonicated for 2 min at
08C to produce a homogeneous dispersion, after which
the diethyl ether was removed by rotatory evapora-
tion under reduced pressure for about 30 min accord-
w xing to the method described by Szoka et al. 26 . The
vesicle suspension was extruded through polycarbon-
ate filters with 1, 0.4 and 0.2 mm pores, successively.
Mean diameters of LUV were determined with a
 .nanosizer apparatus Coulter N4MD . Each sample
was measured three times to obtain an average value
with a standard deviation less than 10%. The mean
diameter was 180 nm. The method of Marshall Stew-
w xart 27 was used to determine the concentration of
phospholipid.
2.4. Hydrophobicity of the anthracycline deri˝ati˝es
An estimation of the hydrophobicity of a com-
pound is given by log P, where P is the partition
coefficient in an n-octanolrwater system. In a first
approximation, the log P value of a compound can be
estimated by adding the f values of its fragmentsi
w x28 . We have determined the variation of log P of
tested compounds using daunorubicin as a reference
compounds and equation
log Ps log P qS f ,0 i
where P is the partition coefficient for daunorubicin0
in n-octanolrwater and f is the n-octanolrwateri
fragmental constant of the fragments of a compound
w xthat differentiate it from daunorubicin 29 . The val-
ues are reported in Fig. 1.
Fig. 1. Structures and relative hydrophobicity values of the
anthracyclines used. Variation of hydrophobicity evaluated as
sum of fragmental values f , referred to daunorubicin.i
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3. Results
The structures of the four anthracycline derivatives
used in the study are shown in Fig. 1.
3.1. Self-association of anthracyclines in aqueous
solution
In aqueous solution, anthracyclines may undergo
the self-association process depending on their con-
centrations. It is already well documented that at high
concentrations drug may be present as a dimer species,
whereas low concentrations favour the formation of
monomeric species. The CD signal observed depends
strongly on the association state of the drug and can
be used as a very efficient tool to indicate whether
w xthe molecules are associated or not 30 . The CD
spectrum of anthracycline in the associated state is
very characteristic and exhibits a signal of the couplet
type in the visible region centered at 480 nm with a
 .positive band at ;460 nm D«;q2 and a nega-
 .  .tive one at ;540 nm D«;y1 Fig. 2 . This
characteristic feature was used to determine the asso-
ciation state of anthracycline in the presence of LUV.
The association constant corresponding to the
dimer formation depends strongly on the presence of
 .the hydroxyl group in position C 13 as well as on
 .that of the methoxy group at C 4 . The comparison of
the CD spectra of doxorubicin and daunorubicin 2=
y3 .10 M with those of idarubicin, that lacks methoxy
 .group at C 4 , shows that while doxorubicin and
daunorubicin exist as dimeric species, idarubicin is
present mainly as a monomeric species. However, the
 .presence of an hydroxyl group in position C 13
causes that idarubicinol exists mainly as a dimer.
Since the CD spectra of the dimeric species exhibit
well defined characteristic negative band at ;
540 nm, not seen in the spectra of the monomeric
 .anthracyclines Fig. 2 , it is possible to use its D«
plotted as a function of the drug concentrations to
estimate the dimerization constant. The calculated
 .values data not shown for the association constants
were found to be 1.1"0.2=104, 8.6"1.6=103
and 2.0"0.5=104 My1 for doxorubicin, daunoru-
bicin and idarubicinol, respectively. In the case of
idarubicin, even at very high drug concentrations
such as 3=10y3 My1, only about 20% of the
molecules are present as dimeric species and we have
just estimated that the order of magnitude of the
constant was 100 My1.
The anthracycline concentration used throughout
the following study was 5=10y4 My1. Experiments
were also performed at lower concentrations 100 and
.50 mM and the data did not depend on the anthra-
cycline concentration.
y3 y5 .  .  .  .Fig. 2. Circular dichroism spectra of daunorubicin DNR , idarubicin IDA and idarubicinol IDOL at 10 M and 10 M
 .
- - - .
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3.2. Interaction of doxorubicin and daunorubicin with
LUV
The interaction of doxorubicin with liposome has
already been studied by different groups and the
specific role of the anionic phospholipids is well
w xdescribed 2–10 . The CD spectra obtained in this
work indicate that when LUV membranes contain
 .high amount of anionic phospholipids 20% , two
step binding of drug molecule can be easily detected.
At low molar ratio PA:DOX, the molecules are bound
through electrostatic interactions involving the nega-
tive charge of the phosphatidic acid and the positive
w xcharge of the amino sugar 7 . The CD spectrum of
the couplet type characteristic for the free dimeric
doxorubicin in aqueous phase disappears and is re-
placed by a positive band of relatively high intensity
 .   ..band I Fig. 3 a . The presence of an isodichroic
point at 450 nm indicates that an equilibrium between
mainly two species, free and bound drug, is present.
In this interaction pattern, the dihydroxyan-
thraquinone moiety lies outside the bilayer in the
bulk of the aqueous medium. When the molar ratio
PA:DOX increases, the intensity of this positive band
decreases and its simultaneous shift to longer wave-
 .lengths is observed band II . This spectrum change
is due to the embedding of the dihydroxyan-
thraquinone moiety inside the bilayer and a preva-
lence of the hydrophobic interactions as compared to
the electrostatic ones. Both, band I and band II are
characteristic of monomeric species. The isodichroic
 .point between band I and II 500 nm indicates that
monomeric species I, with dominantly electrostatic
drug–LUV interactions, and monomeric species II,
with dominantly hydrophobic interactions, are in
equilibrium in the system studied.
When similar CD measurements are performed in
the presence of low amount of anionic phospholipid
 .5% , no band I characteristic for the electrostatic
interactions is observed. The obtained spectrum
changes continuously when LUV is added. An
 .isodichroic point 480 nm from the spectrum of the
dimer in aqueous solution to that of the monomer
 .embedded in the bilayer band II is observed. This
species yielding band II will hereafter be called
monomer II or ‘‘membrane monomer’’. The CD
spectra of doxorubicin, characteristic for the
molecules in the dimeric form in aqueous solution
and bound to the membrane either as monomer I or
 .monomer II, are shown in Fig. 3 b . The presence of
cholesterol in the bilayer does not modified the fea-
tures of these two spectra.
Our experiments have shown that the best condi-
tions to observe the transformations from drug in the
 .  .  .Fig. 3. Circular dichroism spectra of doxorubicin DOX and daunorubicin DNR in the absence of LUV , in the presence of
 .  . w x y4LUV at PA:Anthracyclines1:2 - - - , in the presence of LUV at PC:anthracyclines15 P P P . Anthracycline s5=10 M, DOX
 .  .  .plus LUV containing 20% PA a ; DOX plus LUV containing 5% PA b ; DNR plus LUV containing either 5 or 20% PA c .
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dimeric species to monomer I and then to monomer
II are in the presence of LUV containing 20% PA
following the series:
aqueous dimer no LUV .
“monomer I PA:DOXs1:2 .
“monomer II PL:DOX)10 . .
Using LUV containing none or very low amount
of PA the equilibrium is:
aqueous dimer no LUV .
“monomer II PL:DOX)10 . .
Under the physiological pH conditions, daunoru-
bicin bears exactly the same charge as doxorubicin
and its electrostatic interaction with membrane should
be the same. However, dihydroxyanthraquinone moi-
ety is more lipophilic and, therefore, the hydrophobic
interactions are expected to be stronger than those
observed for doxorubicin. The CD spectra show that
indeed under the same conditions as those used for
doxorubicin, daunorubicin does not exhibit band I
  ..when LUV are added, Fig. 3 c , and the only
species observed is monomer II, with drug molecule
embedded within the polar head of the membrane.
Thus, the CD spectra of daunorubicin, measured with
LUV for different PA:DNR molar ratios exhibiting
  ..isodichroıc point at 480 nm Fig. 3 c , indicate that¨
daunorubicin molecule moves directly from the aque-
ous phase to the embedded site within the polar head
region and the interactions characteristic for monomer
I are of minor, if any, importance for the DNR–LUV
system. Also in this case, the presence of cholesterol
has no influence on the CD spectral pattern of
monomer II.
3.3. Interactions of idarubicin with LUV
Idarubicin molecule is distinctly more lipophilic
than both doxorubicin and daunorubicin. However,
the presence of the same sugar moiety should yield
the same electrostatic interactions as those expected
for doxorubicin and daunorubicin. On the other hand,
at the concentration used in this study, 5=10y4 M,
only 5% of molecules of idarubicin are in the dimeric
form and the CD spectrum is characteristic for a
monomeric species.
The addition of LUV, that contains none or low
amount of phosphatidic acid, gave rise to small modi-
fication of the CD spectrum indicating that the drug
molecule gets embedded inside the bilayer yielding
the membrane monomer. This spectral modifications
did not depend on the presence of cholesterol Fig.
.4 .
However, the addition of LUV that contains 20%
of PA with different amounts of cholesterol yields
very typical CD spectra exhibiting a signal of the
couplet type with a negative band at 435 nm and a
 .positive one at 480 nm Fig. 4 . This CD signal
characteristic for dimeric species, that further we will
call type IX, can be characterised by the A-value
equal to D« -D« , where D« and D« are the1 2 1 2
Cotton effects at the longer and shorter wavelengths,
respectively. Fig. 5 shows the plot of the A-values as
a function of the molar ratio PL:IDA for different
amounts of cholesterol present in the LUV mem-
brane. The data show that the A-value reached a
maximum at PL:IDA molar ratio of 1 for all amounts
of cholesterol used. The A-value obtained at PL:IDA
equal to 1 as a function of the CHOL:IDA molar
ratio increases up to a ratio of 0.3–0.4. At PL:IDA
molar ratios higher than ;4 the CD spectrum char-
 .acteristic of the membrane monomer band II reap-
pears.
Fig. 4. Circular dichroism spectra of idarubicin in the absence of
 .LUV , in the presence of LUV containing PC 40%,
 .  .PA 20%, CHOL 40% at PL:IDA s1:1 - - - ; 5:1 P P P .
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 .Fig. 5. Circular dichroism of idarubicin IDA in the presence of LUV containing PA 20% and various amount of CHOL and PC. Left:
AsD« yD« has been plotted as a function of the ratio PL:IDA for different amounts of cholesterol I, 5%; e, 10%; ‘, 15%; ^,1 2
.35% . Right: the AsD« yD« value obtained at PL:IDAs1 has been plotted as a function of the ratio CHOL:IDA.1 2
3.4. Interaction of idarubicinol with LUV
At the concentration used here LUV-free idarubici-
nol is almost 100% in the dimeric form. Also idarubi-
cinol has the same charge on the amino sugar as the
other three compounds and, thus, the electrostatic
interactions are expected to be very similar to those
of the other drugs studied here. However, idarubici-
nol is the most lipophilic molecule among all four
derivatives discussed here.
The addition of LUV that contained 5% of phos-
phatidic acid and no cholesterol gives rise to the
appearance of the CD spectrum characteristic of a
 .monomer embedded in the bilayer band II, Fig. 6 .
However, the addition of LUV containing 20% PA
and 20–30% CHOL with the PA:IDOL molar ratio of
0.5, results in a CD spectrum exhibiting a negative
band in the visible region. For PL:IDOL molar ratios
higher than 4 one can observe the CD spectrum with
band II characteristic for membrane monomer species.
3.5. Absorption spectra characterisation of the an-
thracycline–LUV interactions
The absorption spectra of anthracycline depend
strongly on the solvent used. The characteristic vibra-
tional fine structure of the absorption band observed
in the visible region becomes better resolved when
dielectric constant of the solvent decreases. As an
example, Fig. 7 shows the absorption spectrum of
idarubicin dissolved in water and DMF, respectively.
Similar spectral modifications are observed for other
 .three compounds data not shown .
 .Fig. 6. Circular dichroism of idarubicinol IDOL in the absence
 .of LUV , in the presence of LUV containing PC
 .40%, PA 20%, CHOL 4O% at PL:IDOL s1:2 - - - or 5:1
 .P P P .
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 .Fig. 7. Absorption spectra of idarubicin in water , in
 .DMF – P – , in the presence of LUV containing PC 40%, PA
 .20%, CHOL 40% at PL:IDA s1:1 - - - .
The absorption spectra of doxorubicin and
daunorubicin bound to the LUV membrane do not
show well resolved vibrational structure, while the
absorption spectra of idarubicin and idarubicinol in-
teracting with LUV membranes show vibrational fine
structure comparable to that observed for free drugs
 .dissolved in DMF Fig. 7 . This clearly indicate that
both idarubicin and idarubicinol are embedded deeper
in the bilayer than the two other drugs doxorubicin
and daunorubicin.
4. Discussion
The impressive affinity of doxorubicin for nega-
tively-charged phospholipids has been the subject of
w xnumerous investigations 2–10 . The ability of dox-
orubicin to participate in such charge–charge interac-
tions at pH 7.4 is due to its protonated amino group,
w xwith a pK s8.4 at 258C 31 . Modification of thisa
pK value can strongly modulate the drug interac-a
tions with charged membranes and, using doxoru-
bicin analogues with low pK values, it was showna
that they do not bind selectively to the negatively
w xcharged phospholipids 14 .
Our study concerns four anthracycline derivatives
which have the same amino sugar and, therefore, the
same electrostatic interaction with LUV, but different
lipophilicity and thus, different ability for embedding
within the bilayer. The conformational modifications
that drugs undergo through interactions with LUV
allow to evaluate the effect of lipophilicity on these
drug–membrane interactions.
Our previous studies have shown ultimately that at
high molar ratio of PL:drug, the same type of binding
is observed for all four derivatives: they are embed-
w xded as monomeric species inside the bilayer 11 . In
addition, doxorubicin and daunorubicin are embedded
within the membrane at the level of the polar head,
i.e. in a medium with an electric permittivity compa-
w xrable to that of methanol 11,32 . However, the
method used did not permit to localise both, idaru-
bicin and idarubicinol, in the membrane bilayer. Nev-
ertheless, the appearance of the well resolved vibra-
tional fine structure in the absorption spectrum allows
to conclude that these two lipophilic compounds are
embedded deeper within the bilayer than doxorubicin
and daunorubicin.
w xBurke et al. 15,16 have examined the effect of
 .valerate substitution at C 14 on the anthracycline
associations with electroneutral dimyristoyl phos-
 .phatidylcholine DMPC bilayers, as well as with
negatively-charged bilayers composed of homoge-
neous dimyristoyl phosphatidylglycerol or with a bi-
 .nary mixture of DMPC and cardiolipin. C 14 -valerate
substitution was found to eliminate the selective bind-
ing of several anthracyclines to negatively-charged
phospholipids, thereby suggesting that a simple syn-
thetic modification might prevent the accumulation of
positively-charged anthracyclines in membranes
abundant in negatively-charged lipid. However, an-
other interpretation can be given and this effect would
 .not be due to the specific substitution at C 14 but to
the fact that the compound thus obtained is much
more lipophilic than doxorubicin. Actually, in the
present paper, we show that the selective binding of
anthracycline to negatively-charged membrane is also
eliminated with compound such as idarubicin where
 .there is no C 14 modification but an increase of the
lipophilicity due to the lack of the methoxy group at
 .C 4 .
We have recently discussed the influence of the
dissymmetry elements of the anthracycline structures
w xon their CD spectra 33 . The molecular shape of the
 .anthracyclines is determined by i the conformation
 .of the sugar ring, ii the conformation of the A ring
 .and iii the orientation of the sugar with respect to
w xthe aglycone moiety 34 . Because of the chro-
mophore–sugar distance, the conformation of the
sugar ring should not affect the CD spectra. Concern-
 .ing the cyclohexene ring A , it has been reported
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that two half-chair conformations are favoured. The
conformation called a is typical of most anthra-
cyclines and is favoured by the hydrogen bond be-
 .  .tween C 9 –OH and C 7 –O and the longer distance
 .  .between phenolic C 6 –OH and C 7 –O, which de-
creases the repulsive interaction between the two
w xcorresponding dipoles 35 . The conformation called
b is observed for 6-deoxyanthracycline derivatives
  .  . . w xno C 6 –C 7 repulsive interaction 36 and for
 . 8- S -fluoroanthracycline derivative configuration at
 .. w x C 8 37 . The CD spectra of idarubicin a confor-
.  .  .mation and 8- S -fluoroidarubicin b conformation
are the same and CD spectroscopy cannot allow the
distinction between the two conformations. It follows
that the geometry of the glycosidic linkage would
have a great impact on the CD signal amplitude at
480 nm. The geometry of the glycosidic linkage can
 .  .  .be defined by the torsional angle C 6a –C 7 –O 7 –
 X.C 1 . In monomeric anthracycline derivatives, in
aqueous solution, the mean plane of the sugar is
perpendicular to the dihydroxyanthraquinone plane.
 .In the case of the ‘‘membrane monomer’’ species II
which is obtained for all anthracyclines at high molar
ratio of phospholipid per drug, the CD signal is
positive, its intensity is lower than that observed for
the monomer in aqueous solution and comparable to
that of the corresponding aglycone. This strongly
suggests that in the ‘‘membrane monomer’’ the value
 .  .  .  X.of the C 6a –C 7 –O 7 –C 1 torsional angle has
changed when compared to the free drug molecule.
At low molar ratio of PA:drug, different anthra-
cycline behaviours are detected depending on their
lipophilicities. Thus, doxorubicin, with its very low
lipophilicity, binds to the LUV through electrostatic
interactions with the dihydroxyanthraquinone moiety
being in the aqueous phase whereas daunorubicin,
which is more lipophilic, is unable to bind only
through electrostatic interactions and the hydrophobic
interactions already play the major role.
The case of idarubicin deserves special comments.
As it was mentioned above the anthracycline deriva-
tives when dissolved at high concentration in aqueous
solutions dimerize and, according to the CD signal of
the couplet type at 480 nm with a negative A-value,
the molecules are associated in the left-handed con-
formation. Both doxorubicin and daunorubicin bind
to membranes as monomers, while the very hy-
drophobic idarubicin, which is more deeply embed-
ded within the bilayer than the two others, forms a
rather complex entity involving 2–3 molecules of
idarubicin associated in the right-handed conforma-
 .tion, one cholesterol molecule and also molecule s
of phosphatidic acid, as this special oligomeric species
is not detected in the absence of negatively-charged
phospholipids.
 .Idarubicinol differs from idarubicin with C 13 –
 .OH instead of C 13 5O and its interactions with
LUV are distinctly different. It does not form any
associations within the bilayer membrane, as it is
attested by the presence of only one band in the
visible. In addition, this band is negative and it
should be noticed that in the case of daunorubicin
which, at low molar ratio of phospholipid per drug, is
also embedded within the bilayer as a monomer, this
signal is positive. The variation of the sign of the
Cotton effect may derive from the changes in the
 .  .  .  X.C 6a –C 7 –O 7 –C 1 torsional angle and it can be
suggested that this is due to the proximity of the
 .  .sugar moiety to the C 5 5O and C 6 –OH functions
to mask the positive charge. It is noteworthy that
 .C 13 –OH group, which strongly favours formation
of the dimeric species in aqueous solutions when
compared to idarubicin prevent association inside
LUV bilayer.
In conclusion, our data show that, whereas the
interactions of doxorubicin and daunorubicin with
membrane are not strongly influenced by the pres-
ence of cholesterol, the interactions of the more
lipophilic idarubicin and idarubicinol depend on the
presence of cholesterol, concomitantly with that of
negatively charged phospholipid. In a biological con-
text, it means that idarubicin and idarubicinol can
recognize cholesterol-rich membrane, whereas dox-
orubicin and daunorubicin cannot. The present find-
ings are of particular interest from a drug-design
standpoint, revealing that lipophilicity may be more
important for the recognition of cholesterol-rich
phospolipids membrane than it has previously been
w xconsidered 38 .
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